NCT05283330 2026-03-20Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing TumorsOrano Med LLCPhase 1 Recruiting48 enrolled